Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registries

A. Ciurea, S. Kissling, A. Götschi, LM. Ørnbjerg, SH. Rasmussen, B. Tamási, B. Möller, MJ. Nissen, B. Glintborg, AG. Loft, A. Scherer, R. Bräm, K. Pavelka, J. Závada, JM. Dias, P. Valente, B. Gudbjornsson, O. Palsson, V. Rantalaiho, R. Peltomaa,...

. 2025 ; 27 (1) : 18. [pub] 20250131

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, pozorovací studie, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010153

BACKGROUND: Efficacy of tumour necrosis factor inhibitors (TNFi) for peripheral arthritis in patients with psoriatic arthritis (PsA) has been established in randomized clinical trials that have used improvement in summated joint counts as an outcome. Whether joints at different anatomical locations might respond differentially to TNFi remains unknown. The aim of the study was to investigate potential variations in the responsiveness to a first tumour necrosis factor inhibitor (TNFi) among joints at distinct locations in patients with psoriatic arthritis (PsA) treated in routine clinical care. METHODS: Bionaive PsA patients from nine European countries were included in this observational cohort study if ≥ 1 joint was swollen at the initiation of a first TNFi as monotherapy or added to methotrexate. Only the 28-joint count was available without imaging data confirming the presence of synovitis. The primary outcome was time to first resolution of joint swelling at each joint level. Hazard ratios (HR) for resolution comparing different joint locations were estimated using interval-censored mixed-effects Cox proportional hazards models, including a random effect for country and patient, adjusted for age and sex. RESULTS: A total of 1729 patients with 8397 swollen joints at the start of TNFi were included. Considering the upper extremity, a higher rate of resolution of joint swelling (HR, 95% CI) was observed for the shoulder (1.65, 1.16-2.35) and elbow (1.90, 1.38-2.61), while a lower rate was found for the wrist (0.72, 0.62-0.83) compared to the joints of digit 3. Within fingers, and using the same reference, joint swelling resolved fastest in digit 4 (1.77, 1.49-2.11) and digit 5 (1.88, 1.53-2.31). A lower rate of resolution of joint swelling was found for the knee in comparison to the elbow, the corresponding joint on the upper limb (0.56, 0.40-0.78). CONCLUSION: The time to resolution of joint swelling upon treatment with TNFi in patients with PsA seems to depend on the localisation of the affected joints.

Aberdeen Centre for Arthritis and Musculoskeletal Health University of Aberdeen Aberdeen UK

Center for Rheumatic Diseases University of Medicine and Pharmacy Bucharest Romania

Center for Treatment of Rheumatic and Musculoskeletal Diseases Diakonhjemmet Hospital Oslo Norway

Centre for Rheumatology Research Landspitali University Hospital Reykjavik Iceland

Centro de Estudos de Doenças Cronicas NOVA Medical School Lisbon Portugal

Copenhagen Center for Arthritis Research Center for Rheumatology and Spine Diseases Centre for Head and Orthopedics Rigshospitalet Glostrup Denmark

DANBIO Registry Rigshospitalet Glostrup Denmark

Department of Clinical Medicine Aarhus University Aarhus Denmark

Department of Clinical Medicine University of Copenhagen Copenhagen Denmark

Department of Clinical Sciences Lund Rheumatology Skåne University Hospital Lund University Lund Sweden

Department of Clinical Sciences Rheumatology Lund University and Skane University Hospital Lund Sweden

Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Rheumatology Aarhus University Hospital Aarhus Denmark

Department of Rheumatology and Immunology Inselspital University Hospital Bern Switzerland

Department of Rheumatology Centro Hospitalar Do Médio Tejo Torres Novas Portugal

Department of Rheumatology Geneva University Hospital Geneva Switzerland

Department of Rheumatology Hospital de Sao Sebastio Centro Hospitalar de Entre O Douro E Vouga Santa Maria da Feira Portugal

Department of Rheumatology Hospital General Universitario Gregorio Marañón Madrid Spain

Department of Rheumatology Inflammation Center Helsinki University Hospital and University of Helsinki Helsinki Finland

Department of Rheumatology Radboud University Medical Center Nijmegen the Netherlands

Department of Rheumatology University Hospital Zurich University of Zurich Rämistrasse 100 Zurich CH 8091 Switzerland

Department of Rheumatology University Medical Centre Ljubljana Ljubljana Slovenia

Faculty of Medicine and Health Technology Tampere University Tampere Finland

Faculty of Medicine Complutense University of Madrid Madrid Spain

Faculty of Medicine University of Iceland Reykjavik Iceland

Faculty of Medicine University of Ljubljana Ljubljana Slovenia

Research Unit Sørlandet Hospital Kristiansand Norway

Rheumatology Unit University of Modena and Reggio Emilia Modena Italy

Statistics Group Swiss Clinical Quality Management in Rheumatic Diseases Foundation Zurich Switzerland

Swiss Ankylosing Spondylitis Association Zurich Switzerland

Swiss Tropical and Public Health Institute Allschwil Switzerland

Tampere University Hospital Centre for Rheumatic Diseases Tampere Finland

University of Basel Basel Switzerland

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010153
003      
CZ-PrNML
005      
20250429134937.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13075-025-03488-w $2 doi
035    __
$a (PubMed)39891200
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Ciurea, Adrian $u Department of Rheumatology, University Hospital Zurich, University of Zurich, Rämistrasse 100, Zurich, CH-8091, Switzerland. adrian.ciurea@usz.ch
245    10
$a Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registries / $c A. Ciurea, S. Kissling, A. Götschi, LM. Ørnbjerg, SH. Rasmussen, B. Tamási, B. Möller, MJ. Nissen, B. Glintborg, AG. Loft, A. Scherer, R. Bräm, K. Pavelka, J. Závada, JM. Dias, P. Valente, B. Gudbjornsson, O. Palsson, V. Rantalaiho, R. Peltomaa, C. Codreanu, C. Mogosan, F. Iannone, M. Sebastiani, GT. Jones, GJ. Macfarlane, I. Castrejon, Z. Rotar, B. Michelsen, JK. Wallman, I. van der Horst-Bruinsma, O. Distler, M. Østergaard, ML. Hetland, R. Micheroli, C. Ospelt
520    9_
$a BACKGROUND: Efficacy of tumour necrosis factor inhibitors (TNFi) for peripheral arthritis in patients with psoriatic arthritis (PsA) has been established in randomized clinical trials that have used improvement in summated joint counts as an outcome. Whether joints at different anatomical locations might respond differentially to TNFi remains unknown. The aim of the study was to investigate potential variations in the responsiveness to a first tumour necrosis factor inhibitor (TNFi) among joints at distinct locations in patients with psoriatic arthritis (PsA) treated in routine clinical care. METHODS: Bionaive PsA patients from nine European countries were included in this observational cohort study if ≥ 1 joint was swollen at the initiation of a first TNFi as monotherapy or added to methotrexate. Only the 28-joint count was available without imaging data confirming the presence of synovitis. The primary outcome was time to first resolution of joint swelling at each joint level. Hazard ratios (HR) for resolution comparing different joint locations were estimated using interval-censored mixed-effects Cox proportional hazards models, including a random effect for country and patient, adjusted for age and sex. RESULTS: A total of 1729 patients with 8397 swollen joints at the start of TNFi were included. Considering the upper extremity, a higher rate of resolution of joint swelling (HR, 95% CI) was observed for the shoulder (1.65, 1.16-2.35) and elbow (1.90, 1.38-2.61), while a lower rate was found for the wrist (0.72, 0.62-0.83) compared to the joints of digit 3. Within fingers, and using the same reference, joint swelling resolved fastest in digit 4 (1.77, 1.49-2.11) and digit 5 (1.88, 1.53-2.31). A lower rate of resolution of joint swelling was found for the knee in comparison to the elbow, the corresponding joint on the upper limb (0.56, 0.40-0.78). CONCLUSION: The time to resolution of joint swelling upon treatment with TNFi in patients with PsA seems to depend on the localisation of the affected joints.
650    _2
$a lidé $7 D006801
650    12
$a psoriatická artritida $x farmakoterapie $7 D015535
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a registrace $7 D012042
650    12
$a antirevmatika $x terapeutické užití $7 D018501
650    _2
$a dospělí $7 D000328
650    _2
$a kohortové studie $7 D015331
650    _2
$a výsledek terapie $7 D016896
650    _2
$a inhibitory TNF $x terapeutické užití $7 D000079424
650    _2
$a TNF-alfa $x antagonisté a inhibitory $7 D014409
650    _2
$a senioři $7 D000368
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Kissling, Seraphina $u Statistics Group, Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) Foundation, Zurich, Switzerland
700    1_
$a Götschi, Andrea $u Statistics Group, Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) Foundation, Zurich, Switzerland
700    1_
$a Ørnbjerg, Lykke Midtbøll $u Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, Denmark
700    1_
$a Rasmussen, Simon Horskjær $u Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, Denmark
700    1_
$a Tamási, Bálint $u Swiss Tropical and Public Health Institute, Allschwil, Switzerland $u University of Basel, Basel, Switzerland
700    1_
$a Möller, Burkhard $u Department of Rheumatology and Immunology, Inselspital University Hospital, Bern, Switzerland
700    1_
$a Nissen, Michael J $u Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland
700    1_
$a Glintborg, Bente $u Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, Denmark $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark $u DANBIO Registry, Rigshospitalet, Glostrup, Denmark
700    1_
$a Loft, Anne Gitte $u DANBIO Registry, Rigshospitalet, Glostrup, Denmark $u Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark $u Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
700    1_
$a Scherer, Almut $u Statistics Group, Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) Foundation, Zurich, Switzerland
700    1_
$a Bräm, René $u Swiss Ankylosing Spondylitis Association, Zurich, Switzerland
700    1_
$a Pavelka, Karel $u Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Závada, Jakub $u Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Dias, Joao Madruga $u Department of Rheumatology, Centro Hospitalar Do Médio Tejo, Torres Novas, Portugal $u Centro de Estudos de Doenças Cronicas, NOVA Medical School, Lisbon, Portugal
700    1_
$a Valente, Paula $u Department of Rheumatology, Hospital de Sao Sebastio, Centro Hospitalar de Entre O Douro E Vouga, Santa Maria da Feira, Portugal
700    1_
$a Gudbjornsson, Bjorn $u Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland $u Faculty of Medicine, University of Iceland, Reykjavik, Iceland
700    1_
$a Palsson, Olafur $u Faculty of Medicine, University of Iceland, Reykjavik, Iceland $u Department of Clinical Sciences, Rheumatology, Lund University and Skane University Hospital, Lund, Sweden
700    1_
$a Rantalaiho, Vappu $u Tampere University Hospital, Centre for Rheumatic Diseases, Tampere, Finland $u Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
700    1_
$a Peltomaa, Ritva $u Department of Rheumatology, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
700    1_
$a Codreanu, Catalin $u Center for Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania
700    1_
$a Mogosan, Corina $u Center for Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania
700    1_
$a Iannone, Florenzo $u Rheumatology Unit, University of Modena and Reggio Emilia, Modena, Italy
700    1_
$a Sebastiani, Marco $u Rheumatology Unit, University of Modena and Reggio Emilia, Modena, Italy
700    1_
$a Jones, Gareth T $u Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, UK
700    1_
$a Macfarlane, Gary J $u Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, UK
700    1_
$a Castrejon, Isabel $u Department of Rheumatology, Hospital General, Universitario Gregorio Marañón, Madrid, Spain $u Faculty of Medicine, Complutense University of Madrid, Madrid, Spain
700    1_
$a Rotar, Ziga $u Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia $u Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
700    1_
$a Michelsen, Brigitte $u Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, Denmark $u Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway $u Research Unit, Sørlandet Hospital, Kristiansand, Norway
700    1_
$a Wallman, Johan K $u Department of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden
700    1_
$a van der Horst-Bruinsma, Irene $u Department of Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands
700    1_
$a Distler, Oliver $u Department of Rheumatology, University Hospital Zurich, University of Zurich, Rämistrasse 100, Zurich, CH-8091, Switzerland
700    1_
$a Østergaard, Mikkel $u Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, Denmark $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
700    1_
$a Hetland, Merete Lund $u Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, Denmark $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark $u DANBIO Registry, Rigshospitalet, Glostrup, Denmark
700    1_
$a Micheroli, Raphael $u Department of Rheumatology, University Hospital Zurich, University of Zurich, Rämistrasse 100, Zurich, CH-8091, Switzerland
700    1_
$a Ospelt, Caroline $u Department of Rheumatology, University Hospital Zurich, University of Zurich, Rämistrasse 100, Zurich, CH-8091, Switzerland
773    0_
$w MED00007534 $t Arthritis research & therapy $x 1478-6362 $g Roč. 27, č. 1 (2025), s. 18
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39891200 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134933 $b ABA008
999    __
$a ok $b bmc $g 2311501 $s 1247234
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 27 $c 1 $d 18 $e 20250131 $i 1478-6362 $m Arthritis research & therapy $n Arthritis Res Ther $x MED00007534
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace